CHRO (Channel Therapeutics) Cash-to-Debt : 0.55 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Channel Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.55.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Channel Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Channel Therapeutics's Cash-to-Debt or its related term are showing as below:

CHRO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.1 Max: No Debt
Current: 0.55

During the past 4 years, Channel Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.10.

CHRO's Cash-to-Debt is ranked worse than
83.13% of 1488 companies
in the Biotechnology industry
Industry Median: 7.4 vs CHRO: 0.55

Channel Therapeutics Cash-to-Debt Historical Data

The historical data trend for Channel Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Channel Therapeutics Cash-to-Debt Chart

Channel Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

0.10

0.08

Channel Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial									0.02	0.08	No Debt	1.52	0.55

Competitive Comparison of Channel Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Channel Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Channel Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Channel Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Channel Therapeutics's Cash-to-Debt falls into.

Channel Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Channel Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.096	/	(1.269	+	0)
	=	0.08

Channel Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.255	/	(2.288	+	0)
	=	0.55

Channel Therapeutics (AMEX:CHRO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Channel Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Channel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728

Website

https://www.channeltherapeutics.com

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Channel Therapeutics Headlines

From GuruFocus

Ikarian Capital, LLC's Strategic Acquisition of Channel Therapeutics Corp Shares

By GuruFocus News • 02-14-2025

Chromocell Announces Stock Repurchase Plan

By Marketwired • 08-07-2024